How often vomiting appears in each document
All three regulators list vomiting for Saxenda®; the EU places it among its very common reactions. [1][2][3] The US and Canadian adult numbers share one pool of five placebo-controlled studies, and the teen numbers come from a single 56-week trial. [1][3] The EU product information, which also covers children from age 6, gives a comparison by age instead of a percentage. [2]
| Document and group | Saxenda® | Placebo | Note |
|---|---|---|---|
| US label, Table 2, adults [1] | 15.7% | 3.9% | 1.7% stopped for vomiting vs under 0.1% |
| Canadian monograph, Table 3, adults [3] | 530 of 3,384 (15.7%) | 75 of 1,941 (3.9%) | Same adult pool |
| US label, Table 3, ages 12–17 [1] | 34.4% | 4.0% | 4.8% stopped for vomiting |
| EU SmPC, Table 4 and text [2] | Very common (≥1 in 10) | — | About 2× in teens vs adults; 2× again in ages 6–11 |
Why the teen figure stands out
In adults, vomiting on Saxenda® was four times the placebo rate. In teenagers it was more than eight times, and roughly one teen in three on liraglutide vomited at least once during the trial. [1] The Canadian monograph and EU summary state the same point plainly: the overall pattern of side effects in adolescents matched adults, except for vomiting, which was about twice as frequent. [2][3]
The adolescent trial gave investigators more room than the adult studies. The dose was raised to 3 mg over 4 to 8 weeks according to tolerability, 82.4% reached 3 mg and 8.8% stayed at 2.4 mg as their highest tolerated dose. [1] The US label lets teenagers who cannot tolerate a step drop back to the previous dose. [1]
In the EU, Saxenda® is also used in children aged 6 to under 12. In that trial, children reported more digestive events on both liraglutide and placebo than older patients, with vomiting about twice as frequent as in adolescents. [2]
What studies add
An early 20-week European trial of liraglutide in adults without diabetes found that 13% of people on 3 mg reported some vomiting, alongside 48% with some nausea, and that most episodes happened during the first six weeks of dose escalation. [4]
A 2025 network meta-analysis of 39 studies with 33,354 adults who had overweight or obesity but no diabetes found that liraglutide, semaglutide, tirzepatide and orforglipron were each linked with a higher vomiting risk than placebo. [5]
In the 2020 adolescent trial publication, 64.8% of teens on liraglutide had digestive adverse events against 36.5% on placebo, and 10.4% stopped because of adverse events, compared with none on placebo. [6]
What can drive it
The label establishes that liraglutide delays gastric emptying and acts on GLP-1 receptors in brain areas that regulate appetite. [1] It names nausea and vomiting as reactions, and builds the five-week dose climb to reduce digestive effects, but does not say which mechanism causes vomiting. [1] Stomach-emptying studies with liraglutide 3 mg are summarised on the Saxenda® nausea page.
Two label points make vomiting more than an inconvenience. First, fluid loss: most post-approval reports of acute kidney injury on liraglutide followed nausea, vomiting or diarrhoea that caused dehydration. [1] Second, a slower stomach: there have been rare reports of inhaled stomach contents during general anaesthesia or deep sedation in people taking GLP-1 medicines, even after fasting. [1]
Overdose is a separate route. Reported overdoses have brought intense vomiting and nausea as well as dangerously low blood sugar; the EU summary records overdoses of up to 72 mg, 24 times the maintenance dose. [1][2]
Other causes to keep in mind
- Stomach infections and food poisoning, especially when others who ate the same food are ill. [7]
- Migraine, motion sickness, pregnancy and strong pain such as kidney stones. [7]
- Slow stomach emptying, or gastroparesis, which MedlinePlus lists as a cause; the US label does not recommend Saxenda® in severe gastroparesis. [1][7]
- Pancreatitis or gallbladder disease, both Saxenda® warnings, when vomiting comes with persistent upper belly pain. [1]
- A blocked bowel, appendicitis or an ulcer, which MedlinePlus lists among serious conditions that can start with vomiting. [7]
Looking after yourself after vomiting
MedlinePlus suggests rinsing your mouth with water after vomiting, sipping clear liquids often rather than drinking a lot at once, and moving on to small, bland meals when food stays down. Sitting quietly can help, while greasy, spicy or strong-smelling food, caffeine, alcohol and fizzy drinks tend to make things worse. [7][8]
The Medication Guide asks you to drink fluids to lower the chance of dehydration, and the EU leaflet points out that fluid loss is most likely at the start of treatment. [1][2] If you vomit after taking other medicines, MedlinePlus advises telling your provider or nurse. [8]
On the dose itself, the label describes delaying a step-up by about a week for adults, or stepping back for teens, and a full restart from 0.6 mg after more than three missed days. [1] Those are decisions for your prescriber.
Saxenda® is a registered trademark of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.
When to get help
| Sign | Who to contact | How fast | Source |
|---|---|---|---|
| Blood or dark, coffee-ground material in the vomit | Emergency number or emergency room | Emergency | MedlinePlus [7] |
| Severe belly pain that will not go away, sometimes through to the back, with vomiting | Stop Saxenda® and get medical help straight away | Emergency | Medication Guide [1]; EU leaflet [2] |
| More Saxenda® injected than prescribed | Poison Help (US 1-800-222-1222), a doctor or the nearest emergency room | Emergency | Medication Guide [1]; EU leaflet [2] |
| Vomiting for over 24 hours, no fluids kept down for 12 hours, or no urine for 8 hours | A doctor or urgent care the same day | Today | MedlinePlus [7] |
| Vomiting three or more times in one day, or with a headache and stiff neck | A doctor the same day | Today | MedlinePlus [7] |
| An operation or procedure with anaesthesia or sedation coming up | Tell the surgical team you use Saxenda® | At your next appointment | Prescribing Information [1] |
